MC and WGs joint meetingAction BM1206

12th March 2014, Barcelona

ESF provides the COST Officethrough a European Commission contract

COST is supported by the EU Framework Programme

COST Domain - Biomedicine and Molecular Biosciences (BMBS)

12th March 2014, BarcelonaCentre Esther Koplowitz, IDIBAPS

COOPERATION STUDIES ON INHERITED SUSCEPTIBILITYTO COLORECTAL CANCER

Sergi Castellví-Bel

Welcome to Barcelona!

2

Welcome to Barcelona!

• PLEASE REMEMBER TO SIGN ATTENDANCE LIST

• WIFI ACCESS: HOTSPOT CLINIC

• ADOPTION OF AGENDA (approval)

3

• APPROVAL OF EDINBURGH MEETING MINUTES

• UPDATE ON THE ACTION

Status of the Action

• Participating countries: (proposal) Austria, Czech Republic, Finland, Germany,Italy, Netherlands, Portugal, Spain, Sweden, United Kingdom; (joined afterapproval) Cyprus, France, fYR Macedonia, Israel, Malta, Romania, Turkey,Greece, Norway, Ireland, Serbia, Croatia

• France dropped out of the Action (17/09/13)

• 21 current participating countries(97 listed participants)

4

• ACTION BUDGET STATUS:1st year, 1st installment received(65%, 55,900€);

Top up for 2nd installment due toincrease in number of participating countriesapproved! (43.450€)

TOTAL BUDGET for 1 st year: 99.350€

Objectives of the network

Main objective: to comprehensively understand the impact of inheritedsusceptibility in colorectal cancer (CRC) for profiling individual disease risk andperforming early screening and treatment monitoring

NEW MOLECULAR BIOMARKERS WILL BE IMPLEMENTED AND VALIDATED FOR PERSONALIZED CRC MEDICINE

• Specific objectives:

5

� Identification of new CRC susceptibility variants (Obj.1)

� To pinpoint functional links for CRC susceptibility variants (Obj.2)

� To link genetic variants to CRC survival and treatment toxicity (Obj.3)

� To identify genetic variants enriched in CRC subgroups (Obj.4)

Objectives of the network

• Specific objectives (cont.):

� To discover new predisposition genes for CRC in families with unknowngenetic basis (Obj.5)

� To detect interactions between CRC susceptibility variants andenvironment (Obj.6)

6

� To develop a high-risk CRC profile of inherited variants by statisticalmodeling (Obj.7)

� Articulation and strengthening of cooperative research

� Gender balance and implication of early-stage researchers

� Dissemination of results and involvement of stakeholders

Network management and organisation

• This Action’s activities will be organized in four Working Groups:

� Genetic Association Studies (WG1)

� Functional Genomics (WG2)

� Next Generation Sequencing (WG3)

� Statistical Modeling (WG4)

• Networking by regular meetings, e-mailing and video conferences.

7

• Networking by regular meetings, e-mailing and video conferences.Annual work, budget and dissemination plans

• MC/WG meetings (2 per year) and Core Group meetings (if necessary),invited external experts

• Workshops/conference (1 per year): in conjunction with a MC meeting ora scientific-related event, involvement of early-stage researchers

• Short Term Scientific Missions (STSMs): particularly for young scientists

• Training schools: Intensive training on a new and emerging subjectrelevant to the Action’s objectives (2nd year)

Distribution of Action’s tasks

Management committeeGrant Holder: IDIBAPS, ES; www.idibaps.orgChair of the Action: Sergi Castellví-Bel, ESVice-chair of the Action: Annika Lindblom, SE

Working Group chairs- Genetic Association Studies (WG1): Ian Tomlinson, UK (chair), Dina Ruano, NL (vice-chair)- Functional Genomics (WG2): José Luis Goméz-Skarmeta, ES (chair), Richard Houlston, UK (vice-chair)- Next Generation Sequencing (WG3): Tom van Wezel, NL (chair), Claire

8

- Next Generation Sequencing (WG3): Tom van Wezel, NL (chair), Claire Palles (vice-chair)- Statistical Modeling (WG4): Albert Tenesa, UK (chair), Ceres Fernández-Rozadilla, UK (vice-chair)

Financial rapporteurs: Clara Ruiz-Ponte, ES and Jochen Hampe, DESTSMs committee: Kari Hemminki, DE (chair), Andrea Gsur, AT, Lauri Aaltonen, FIPublications committee: Ian Tomlinson, UK, Vanessa Petroni, MT, Web site committee: Sergi Castellví-Bel, ES and Pavel Vodicka, CZ

Short Term Scientific Missions (STSMs)

• The aim of a STSM is to contribute to the scientific objectives of a COST Action

• These Missions (Exchange Visits) are aimed at strengthening the existingnetworks by allowing scientists to go to an institution or laboratory in anotherCOST Country to foster collaboration, to learn a new technique or to takemeasurements using instruments and/or methods not available in their owninstitution/laboratory. They are particularly intended for young scientists

• Standard duration: minimum 5 days, maximum 90 days

• Extended duration for Early Stage Researchers (ESR, postdoc up to 8 years

9

• Extended duration for Early Stage Researchers (ESR, postdoc up to 8 yearsafter PhD): minimum 91 days, maximum 180 days

• Please refer to COST Vademecum for more detailed information and applythrough https://e-services.cost.eu/stsm

• STSM Committee: Kari Hemminki (chair), Andrea Gsur, Lauri Aaltonen

• This Action already opened a first call for STSMs. This first year 2 STSMs tookplace so far. Still some budget available. Please express your interest.

Gender balance and early-stage researchers

• Gender balance always respected in this Action’s activities

• Increase involvement of female and early-stage researchers by invitingthem to actively participate in this Action

• MC involves 7/17 females (41%) and 10/17 young researchers (59%)to ensure commitment

• 24/48 females (50%) and 21/48 young researchers (44%) in this

10

• 24/48 females (50%) and 21/48 young researchers (44%) in thismeeting

• Balance training activities and STSMs among genders

• STSMs particularly for young researchers

• Seeking the participation of early-stage researchers will ensure thecontinuation of this Action’s activities beyond the grant period

Dissemination planning• Initial brochure:

� Designed ; 2,000 copies printed

� 50 copies handed to each group during this meeting and previous

� Aimed to be distributed actively to potential new participants

• Website:

�www.eucolongene.eu

�user: eucolongene, password:eu1206csi (for members area)

11

� Check that your data is correct; send photo if not available

� Contribute with useful material (publications, EU grant info)

• Publications:

� Please acknowledge COST Action BM1206 in your publications:

� “This publication is supported by COST Action BM1206”

� Send pdf of your publications

� 2 papers in PLoS ONE already paid (CASP8 and K618A MLH1)

COST countries

• 28 EU members: Austria,Belgium, Bulgaria, Croatia,Cyprus, Czech Republic,Denmark, Estonia, Finland,France, Germany, Greece,Hungary, Ireland, Italy, Latvia,Lithuania, Luxembourg, Malta,Netherlands, Poland, Portugal,Romania, Slovakia, Slovenia,Spain, Sweden, United Kingdom

12

• EFTA countries: Iceland, Norway,Switzerland

• EU candidates: fYR Macedonia,Turkey

• EU potential candidates: Bosniaand Herzegovina, Serbia

• Cooperating State: Israel

36 COUNTRIES

Working groups (scientific strategy)

• This Action’s activities will be organized in four Working Groups:

� Genetic Association Studies (WG1) will comprise all activities relatedto the identification of new CRC genetic susceptibility variants andcorrelation of known and newly identified CRC genetic susceptibilityvariants with CRC survival and treatment response, as well as withCRC subtypes.

� Functional Genomics (WG2) will cover research undertaken byparticipants regarding fine mapping and functional studies for knownand newly identified CRC genetic susceptibility variants.

13

and newly identified CRC genetic susceptibility variants.

� Next Generation Sequencing (WG3) will include all activities relatedto the identification of new predisposition CRC genes by nextgeneration sequencing.

� Statistical Modeling (WG4) will consist of research tasks involved instatistical analyses of gene-gene (epistasis and hereditary CRCmodifiers) and gene-environment interactions for CRC geneticsusceptibility variants, with a final objective of developing a high-riskprofile for CRC to be used as a molecular tool for personalized CRCmedicine.

• IDENTIFICATION OF NEW CRC SUSCEPTIBILITY VARIANTS

• GENETIC VARIANTS INVOLVED IN CRC SURVIVAL ANDTREATMENT TOXICITY

• GENETIC VARIANTS ENRICHED IN CRC SUBGROUPS

• NEW PREDISPOSITION GENES FOR CRC IN FAMILIES WITHUNKNOWN GENETIC BASIS

COST MoU objectives for the 1 st year

14

� 2 MC/WG joint meetings (Edinburgh and Barcelona)

� Translational Genomics in Biomedicine workshop (Barcelona)

• STSMs: 4 available for 1st year (2 already)

� Dissemination: brochure, website (and publications)

� Financial administration/coordination: IDIBAPS

15

COST countries

• 28 EU members: Austria,Belgium, Bulgaria, Croatia,Cyprus, Czech Republic,Denmark, Estonia, Finland,France, Germany, Greece,Hungary, Ireland, Italy, Latvia,Lithuania, Luxembourg, Malta,Netherlands, Poland, Portugal,Romania, Slovakia, Slovenia,Spain, Sweden, United Kingdom

16

• EFTA countries: Iceland, Norway,Switzerland

• EU candidates: fYR Macedonia,Turkey

• EU potential candidates: Bosniaand Herzegovina, Serbia

• Cooperating State: Israel

36 COUNTRIES

Non-COST application to this Action

• Non-COST countries: all the other

• On the basis of mutual benefit. Cannot participate in MC or be reimbursed

• Dr Luis CARVAJAL-CARMONAGenome Center & Department of Biochemistry and Molecular MedicineSchool of Medicine

17

School of MedicineUniversity of California, Davis (UC Davis), USA(as stated originally in full proposal)It is going to be official after this meeting

• Other applications?

Location and date of next activities

•Translational Genomics in Biomedicine workshop: 13-14/03/2014

• Candidate locations for 2nd year meetings: Prague, Vienna, Porto, Groningen, Leiden, Tel Aviv, Istanbul and Milano

• Dates? September 2014-March 2015

18

• Ideas for a training school for 2nd year: Next-generation sequencing analysis, basic tools for tumor analysis in hereditary CRC and functional studies platform

• Workshop 2015: application to "Current Trends in Biomedicine“ programme at International University of Andalusia (UNIA) to be held in autumn 2015 if succesful

EU applications – Horizon2020

• Call info available at our website

• There was initial intentions to apply for ERA-NET on Translational Cancer Research (TRANSCAN) - Joint Transnational Call for Proposals2013 (JTC 2013) on "Translational research on tertiary prevention in cancer patients” leaded by Jochen Hampe but finally not presented

19

• There has been an application to PHC 5 – 2014: Health promotion and disease prevention: translating ‘omics’ into stratified approaches leaded by Ian Tomlinson with some groups participating

• There can be other in the future

• IDENTIFICATION OF NEW CRC SUSCEPTIBILITY VARIANTS

• GENETIC VARIANTS INVOLVED IN CRC SURVIVAL ANDTREATMENT TOXICITY

• GENETIC VARIANTS ENRICHED IN CRC SUBGROUPS

• NEW PREDISPOSITION GENES FOR CRC IN FAMILIES WITHUNKNOWN GENETIC BASIS

COST MoU objectives for the 1 st year

20

� 2 MC/WG joint meetings (Edinburgh and Barcelona)

� Translational Genomics in Biomedicine workshop (Barcelona)

• STSMs: 4 available for 1st year

� Dissemination: brochure, website (and publications)

� Financial administration/coordination: IDIBAPS

• IDENTIFICATION OF NEW CRC SUSCEPTIBILITY VARIANTS

• NEW PREDISPOSITION GENES FOR CRC IN FAMILIES WITHUNKNOWN GENETIC BASIS

• FUNCTIONAL LINKS FOR CRC SUSCEPTIBILITY VARIANTS

• INTERACTIONS BETWEEN CRC SUSCEPTIBILITY VARIANTS AND

COST MoU objectives for the 2 nd year

21

• INTERACTIONS BETWEEN CRC SUSCEPTIBILITY VARIANTS ANDENVIRONMENT

• HIGH RISK CRC PROFILE OF INHERITED VARIANTS BYSTATISTICAL MODELLING

• 1/2 MC/WG joint meetings: city/cities to be decided

• Training school: topic and city to be decided

• STSMs: number available depending on interest

� Dissemination: website and publications (open access fees can be

COST MoU objectives for the 2 nd year

22

� Dissemination: website and publications (open access fees can becovered for those related to this Action’s objectives)

� Financial administration/coordination: IDIBAPS

COST travel reimbursement 101

• Pay in advance – be reimbursed after the meeting rule

• Pay attention to rules in COST Vademecum (no excessive expense, economy class, flat rate for accommodation and meals, no taxis)

• Use e-COST

• Remember to attach flying ticket/e-ticket showing name, price and itinerary

23

• We need original tickets for any exceptional cost different from flat rates

• Give to me the signed generated Travel Reimbursement Request (TRR) or send to:Dr Juan Manuel ABOLAFIA MOYAConsorci Institut D'Investigacions Biomediques August Pi i SunyerRossello 14908036 Barcelona, Spain

• Deadline to receive TRR: 12/14/2014 (those received will be paid)